Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Telomerase Dysfunction Strategy Overcomes Targeted Therapy Induced Drug Tolerant Persister in Pan-cancer via SUCLG2 downregulation

ABSTRACT: The evolution of cancer cells from a drug-tolerant persister (DTP) state into stably resistant clones is a primary barrier to the long-term efficacy of targeted therapies. Through longitudinal transcriptomic profiling across melanoma, non-small cell lung cancer (NSCLC), and colorectal cancer models, we uncover a conserved, biphasic regulation of telomerase as a fundamental driver of this process. Combining targeted therapies with telomerase inhibition (genetic or pharmacological) in melanoma and NSCLC models suppressed DTP cell formation and resistance progression in vitro and in vivo. Mechanistic dissection via RNA-seq revealed SUCLG2 as a critical downstream effector of the telomerase inhibitor 6-thio-dG; SUCLG2 knockdown phenocopied combinatorial efficacy. Complementary ATAC-seq demonstrated 6-thio-dG–induced chromatin remodelling at the SUCLG2 locus, reducing accessibility to downregulate expression and thereby impeding DTP proliferation and resistance evolution. Collectively, we establish preemptive telomerase inhibition as a vulnerability-directed strategy to ablate adaptive resistance across malignancies.

ORGANISM(S): Homo sapiens

PROVIDER: GSE308782 | GEO | 2026/05/21

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

A telomerase-SUCLG2 signaling axis drives drug resistance by protecting persister cells

Project description:The evolution of drug-tolerant persister (DTP) cells into resistant clones remains a major obstacle to targeted therapies. Transcriptomic profiling across melanoma (A375, SK-MEL-28), non-small cell lung cancer (NSCLC; HCC827, PC-9), and colorectal cancer (CRC; SW480) models revealed a conserved biphasic telomerase regulation during DTP evolution. Combining targeted therapies with the telomere-dysfunction agent 6-thio-dG effectively suppressed DTP outgrowth and resistance in vitro and in vivo. Mechanistically, 6-thio-dG induces chromatin remodeling, reducing SUCLG2 locus accessibility and downregulating this mitochondrial enzyme to disrupt DTP metabolic stability. Consistently, SUCLG2 knockdown recapitulated these therapeutic effects. Furthermore, in vivo RNAseq of HCC827 xenografts confirmed the combination coordinately suppresses mitochondrial metabolism, telomere maintenance, and persister programs. Collectively, preemptively combining 6-thio-dG with targeted therapies is a potent strategy to disrupt DTP evolution and overcome adaptive resistance across diverse malignancies.

2026-05-21 | GSE329254 | GEO

A telomerase-SUCLG2 signaling axis drives drug resistance by protecting persister cells [ATAC-Seq]

2026-05-21 | GSE331127 | GEO

Telomerase-mediated Strategy for Overcoming Non-Small Cell Lung Cancer Targeted Therapy and Multi-drug Chemotherapy Resistance

Project description:Standard and targeted therapies almost universally fail due to tumor heterogeneity/plasticity leading to intrinsic or acquired drug resistance. We used the telomerase substrate precursor 6-thio-2’-deoxyguanosine (6-thio-dG) to target telomerase-expressing targeted therapy and platin-doublet chemotherapy resistant cells. We observed that erlotinib, paclitaxel/carboplatin and gemcitabine/cisplatin resistant cells are sensitive to 6-thio-dG in xenograft, syngeneic immunocompetent and genetically engineered mouse models. We also show sensitivity to 6-thio-dG on a large panel of non-small cell lung cancer cell lines (73 of 77). The 4 resistant NSCLC lines clustered together, providing a molecular signature for patients that may not respond to 6-thio-dG. We find SLC43A3 as a top candidate in this molecular signature. Thus, 6-thio-dG may prolong disease control of therapy-resistant lung cancer patients.

2018-01-30 | GSE109821 | GEO

Gene Expression Analysis of Melanoma Cells Treated with 6-Thio-dG In Vitro

Project description:Telomerase promoter mutations are highly prevalent in human tumors including melanoma. Telomere transcriptional signatures are enriched in a subset of therapy-naïve melanomas associated with worse overall survival, in BRAF-mutant intrinsically resistant melanoma cells that evade MAPK inhibitors (MAPKi), as well as in a subset of post-treatment tumor biopsies derived from patients who have disease progression on MAPKi or the immune checkpoint inhibitors, anti-CTLA-4 or anti-PD1. We demonstrate the efficacy of a telomerase-directed nucleoside, 6-thio-2'-deoxyguanosine (6-thio-dG) that results in telomere dysfunction and cell death in various models of therapy-resistant cells. Furthermore, 6-thio-dG significantly inhibits tumor growth of primary tumor biopsy cultures derived from patients who had disease progression on multiple therapies including anti-CTLA-4 or anti-PD1.

2017-06-02 | GSE99552 | GEO

Suclg2 maintains the tolerogenic function of regulatory dendritic cells by suppressing Lactb succinylation [si-nc/si-Suclg2]

Project description:Purpose: mRNAs sequencing of the gene expression differences in diffDC transfected with si-nc or si-Suclg2, the goals of this study are to investigate the biological effect of the metabolic enzyme succinate-CoA ligase subunit beta Suclg2 in regulating regulatory DC differentiation and function.

2023-11-27 | GSE220055 | GEO

Exploring the Effect and Mechanisms of Telomerase Inhibition as A Novel Therapeutic Strategy for Glioma [2224, DBTGR-05MG, A172]

Project description:The obejctive of this study is to establish the therapeutic role of 6-thio-dG for gliomas in vitro and in vivo and to elucidate the anti-tumor mechanisms of 6-thio-dG in glioma cells. And the ultimate goal of this proposal is to demonstrate the potential of 6-thio-dG as a novel strategy for primary and recurrent glioma.

2021-09-13 | GSE180874 | GEO

Exploring the Effect and Mechanisms of Telomerase Inhibition as A Novel Therapeutic Strategy for Glioma

2021-09-13 | GSE160619 | GEO

Suclg2 maintains the tolerogenic function of regulatory dendritic cells by suppressing Lactb succinylation [si-nc/si-Suclg2]

Project description:Suclg2 maintains the tolerogenic function of regulatory dendritic cells by suppressing Lactb succinylation [si-nc/si-Suclg2]

| PRJNA908261 | ENA

Suclg2 maintains the tolerogenic function of regulatory dendritic cells by suppressing Lactb succinylation

Project description:Purpose: mRNAs sequencing of the gene expression differences in maDC and diffDC, the goals of this study are to investigate the biological effect of the metabolic enzyme succinate-CoA ligase subunit beta Suclg2 in regulating regulatory DC differentiation and function.

2023-11-27 | GSE219010 | GEO

Homo sapiens

Project description:Gene Expression Analysis of Melanoma Cells Treated with 6-Thio-dG In Vitro

| PRJNA388966 | ENA